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New tools are required to ensure the adequate control of the neglected tropical disease human African trypanosomiasis. 
Annual reports of infection have recently fallen to fewer than 5000 cases per year; however, current therapies are hard to 
administer and have safety concerns, hence are far from ideal. Trypanosome alternative oxidase is an exciting target for 
controlling the infection; it is unique to the parasite and inhibition of this enzyme with the natural product ascofuranone 
has shown to clear in vivo infections. We report the synthesis and associated structure activity relationships of inhibitors 
based upon this natural product with correlation to T. b. brucei growth inhibition in an attempt to generate molecules that 
possess improved physicochemical properties and potential for use as new treatments for human African trypanosomiasis. 
Keywords: Medicinal chemistry, drug design, multiparam-
eter optimisation, human African trypanosomiasis. 
 
Human African trypanosomiasis (HAT), otherwise known 
as African sleeping sickness, is a neglected tropical disease 
caused by human infection by the protozoan parasites T. b. 
gambiense or T. b. rhodesiense, transmitted by tsetse flies 
in sub-Saharan Africa.1 Without treatment, HAT is invari-
ably fatal;2 the drugs that are currently approved for treat-
ment of both the haemolymphatic (stage 1) and en-
cenphalitic (stage 2) phases of the disease have either toxic 
side effects or require complex administration procedures.3 
Resistant strains of the parasites have been observed in the 
clinic and there is a requirement for new treatment options 
to guarantee the successful control of the disease.4,5 In 
2009 it was estimated that occurrences of the disease had 
fallen below 20 000 incidences a year and that 65 million 
people are at risk of transmission.1 
The trypanosome, first discovered by Sir David Bruce in 
1894,6 undergoes diverse lifecycle adaptations conferring 
viability in both the tsetse fly vector and mammalian 
host.7,8 A predominant feature of Trypanosoma brucei is 
that it is capable of successfully evading host immune re-
sponses, predominantly due to its capacity to diversify the 
surface antigens that it presents to its host;9 this ability has 
been a major factor for preventing the development of an 
efficacious vaccine against the pathogen.10 T. b. gambiense 
is responsible for >95% of cases of HAT and is a zoonotic 
disease, residing in a variety of domestic animals and live-
stock.11 Trypanosome infection in cattle and other livestock 
also has a large burden on the health and associated eco-
nomic output of animals; the cost of delivering trypano-
cidal agents to control ‘Nagana’ or African animal trypano-
somiasis (AAT) is estimated to be 140 million USD per 
year.12 
Current treatments for HAT are far from ideal. Stage 1 of 
the disease is treated with suramin for T. b. rhodesiense or 
pentamidine for T. b. gambiense, both compounds display 
undesired toxic side effects in the clinic.13 Resistance 
against pentamidine has also been observed and linked to 
mutations in the P2 amino purine and other trypanosome 
uptake transporters.5 Both suramin and pentamidine are 
unable to permeate into the CNS to sufficient levels, and 
thus are ineffective against stage 2 infections.14 The organo-
arsenide melarsoprol and the more recent combination 
therapy of nifurtimox and eflornithine (NECT) are cur-
rently used to treat infections of T. b. gambiense and T. b. 
rhodesiense respectively. Both treatments have their limi-
tations. Melarsoprol shows significant toxic effects in those 
treated, causing encephalopathy in 5-10% of people treated 
with the drug.15 Incidences of resistance to melarsoprol are 
becoming more commonplace, again linked to mutations 
in the P2 amino purine uptake transporters; associated fail-
ure rates in the clinic have been reported to be between 
20%-30% in the early 2000’s.5 NECT requires the admin-
istration of eflornithine via slow intravenous infusion of 
200 mg/kg every 12 hours for 7 days as it is only trypanos-
tatic, thus requiring trypanocidal action by the co-admin-
istered nifurtimox and innate host clearance mecha-
nisms.16 
With the limitations of the currently approved medicines 
for treating HAT and the increasing reports of resistance to 
these therapies, it is vital to discover new and improved 
treatments against the pathogen. An ideal target for drug 
discovery for HAT is the trypanosome alternative oxidase 
(TAO).17 TAO is the sole terminal oxidase enzyme in the 
 aerobic respiratory pathway for the long slender blood 
stage form of Trypanosoma brucei subspecies. The enzyme 
utilises oxygen and ubiquinol as substrates for the efficient 
generation of cellular ATP as the parasite does not express 
regular cytochrome respiratory complexes.18 TAO is a di-
iron (non-heme) oxidoreductase that is located in the in-
ner-mitochondrial membrane of the trypanosome.19 As 
TAO is not found in mammalian systems, there is a unique 
opportunity to attain compounds with enhanced selectiv-
ity and circumvent on-target toxicity.19 It has recently been 
reported that the pentamidine and melarsoprol drug re-
sistant parasites have an increased sensitivity to inhibition 
of TAO, as these parasites have a reduced capacity to efflux 
cellular glycerol that is produced as the result of anaerobic 
respiration.20 The crystal structure of TAO has been re-
ported, allowing a structure based design approach to new 
molecules.21 Nanomolar inhibition of TAO has been re-
ported with the natural product ascofuranone (AF (1)) and 
its analogues in validated biochemical assays,22 demon-
strating correlation in ex vivo growth inhibition23 and effi-
cacy in in vivo clearance models.24 
 
Figure 1. Summary of previous work23 
Our previous work identified robust synthetic routes to 
close analogues of AF (1) and structure activity relation-
ships of the synthesized molecules, highlighting the re-
quirement of both the chloro and methyl substituents on 
the aromatic ring for high potency (figure 1).23 With these 
routes in place we set out to further explore structurally 
similar analogues with the aim to reduce lipophilicity, and 
improve the drug like properties of these molecules. Our 
aim of reducing lipophilicity was to specifically improve 
aqueous solubility, decrease metabolism and improve the 
potential to achieve efficacious CNS concentrations, as 
new compounds for HAT must be effective against both 
stages of the disease. 
There are many hurdles preventing permeability of organic 
drug molecules to the brain. The blood brain barrier pro-
vides significant protection to xenobiotics; tight junctions 
around capillaries prevent permeation and the expression 
of ABC-transporters actively transport solubilised organic 
molecules out and away from the barrier and the brain.25 
Compounds that traverse readily into the CNS tend to have 
high passive permeability, have low efflux from ABC-
transporters like P-glyco-protein (P-gp) and have low met-
abolic turnover in human liver microsomes, providing the 
basis for the generation of a predictive scoring tool for CNS 
penetration.26 
A major contribution to the poor multi-parameter optimi-
sation (MPO)26 predicted CNS-penetration score for AF (1) 
and colletochlorin B (CCB (2)) is attributed to its high lip-
ophilicity. Clearly the major contributor to the high lipo-
philicity of CCB (2) is from the geranyl ‘lipophilic tail’ (fig-
ure 2). Compounds with a cLogP above 5 are commonly 
observed to be P-gp substrates, and tend to have a high 
metabolic liability. We herein report the synthesis and SAR 
investigation of analogues focused on reducing the lipo-
philicity of the tail region of structural analogues of AF (1) 
and CCB (2), with an aim to improve physicochemical 
properties and increase the predicted CNS penetration 
MPO score. 
Figure 2. Per atom contribution to lipophilicity of asco-
furanone (AF) (1) and colletochlorin B (CCB) (2) 
Results and Discussion 
The biochemical assessment of the bicyclic 1,2-isoxazole 
intermediate prepared to access the aldehyde replacement 
with the nitrile analogue of CCB (2), had shown unexpect-
edly high potency for inhibiting TAO. Previous reports had 
postulated that a hydrogen bond donor was needed at this 
position for potent inhibition of TAO.22 
 
Figure 3. Isoxazole Kemp elimination 
To confirm this result, a synthetic route to the mono phe-
nolic compound (11) was devised (scheme 1), to rule out the 
activity arising from an in situ formation of nitrile com-




 Scheme 1. Mono-phenol analogue synthesis 
 
Reaction conditions: a) trimethylphenylammonium tribro-
mide, CH2Cl2 / MeOH rt, 3 h, 77%, b) NH2OH·HCl, EtOH, re-
flux, 16 h, 90%, c) NCS, Et3N, MeCN, 0°C – rt, 16 h, 70%, d) 
dimethyl sulfate, acetone, rt, 16 h, 98%, e) i) BH3·THF, 1-oc-
tene, 0°C, 20 min, ii) toluene, H2O, K3PO4, RuPhos, Pd(OAc)2, 
50°C, 16 h, 90% f) TMS-Cl, NaI, MeCN, 80°C, 16 h, 65%. 
Selective bromination of the phenolic aldehyde was 
achieved by treatment with trimethylbenzylammonium 
tribromide at 0 °C; non-selective and over bromination was 
observed using N-bromosuccinimide.28 The aldehyde (6) 
could be successfully converted to the nitrile (7) by oxime 
formation with hydroxylamine hydrochloride and subse-
quent in situ dehydration. Protection of the phenol (8) to 
the anisole (9) with dimethylsulfate was required to facili-
tate a high yielding Suzuki-Miyaura cross-coupling using 
tri-n-octylborane as the coupling partner that was formed 
in situ by reacting 1-octene with a solution of 1M borane in 
THF.29 Final deprotection of the anisol (10) to the free phe-
nol using trimethylsilyl chloride and sodium iodide pro-
vided the monophenol analogue (11) for biochemical and 
ex vivo assessment (table 1).30 
 
 
Table 1. Biological assay assessment of isoxazole and mono-phenol analogues 
# Structure TAO pIC50† T. b. b. pEC50* HepG2 pCC50# 
2 
 
8.5 ± 0.3 8.4 ± 0.1 5.1 ± 0.1 
4 
 
8.4 ± 0.2 6.4 ± 0.1 4.9 ± 0.1 
3 
 
8.3 ± 0.4 7.0 ± 0.2 5.3 ± 0.2 
11 
 
8.9 ± 0.3 7.6 ± 0.1 5.1 ± 0.1 
46 
 
7.0 ± 0.1 5.1 ± 0.2 4.7 ± 0.1 
10 
 
4.5 ± 0.1 < 4.3 < 4.3 
†: Negative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome alternative oxi-
dase; *: Negative log concentration and standard deviation of compounds required for 50% growth inhibition of T. b. brucei Lis-
ter427; #: Negative log concentration and standard deviation of compounds required for 50% cytotoxicity of HepG2 cell line. (n ≥ 
2 in all assays)
Interestingly, the monophenol analogue (11) retained high 
potency against TAO that corresponded to the most potent 
inhibition of T. b. brucei growth for a compound not con-
taining the benzaldehyde functionality present in AF and 
 CCB. The removal of one of the flanking substituents ortho 
to the brominated coupling position facilitated its reactiv-
ity and thus exploration of this tail. This synthetic route 
was adopted for further diversification of this tail region. 
The des-methyl starting material was accessible from com-
mercially available sources and was used to initially inves-
tigate tail modifications. 
The introduction of polarity into the lipophilic tail was de-
vised to reduce cLogP and improve upon the predicted 
CNS penetration MPO score (>4 required for high pre-
dicted CNS exposure). The introduction of amide function-
ality in alternate positions in the chain were planned to 
mimic the n-octyl (C8H17) or geranyl chain. The inclusion 
of the amide functionality had the largest predicted im-
provement to both cLogP and MPO score (Row C – table 
2). 1-Alkene esters were converted to trialkylboranes using 
the methodology previously employed to access the n-octyl 
analogues (scheme 2). These were then coupled with the 
brominated intermediate (14). The esters were converted 
to the desired amides by either in situ hydrolysis under the 
demethylation conditions, with subsequent HATU amide 
coupling with the required alkylamine, or a direct aminol-
ysis of the ester by using 1,5,7-triazabicyclo[4.4.0]dec-5-ene 
(TBD) and the desired alkylamine with subsequent anisole 
deprotection with TMSCl / NaI to provide the amide chain 
compounds for biological assessment (table 3).31 
Table 2. cLogP and predicted MPO scores for planned 
analogues. 



















cLogP calculated from ChemAxon Marvin Sketch, calculated 
MPO as described by Wager et al.26 
Scheme 2. Amide tail linker synthesis 
 
Reaction conditions: a) NBS, MeCN, rt, 16 h, 85%, b) dimethyl 
sulfate, acetone, reflux, 3 h, 90%, c) i) BH3·THF, 1-alkene ester, 
0 °C, 20 min, ii) toluene, H2O, K3PO4, RuPhos, Pd(OAc)2, 16 h, 
50°C, 90%, d) TMSCl, NaI, MeCN, 80 °C, 16 h, 35-85%. e) 
HATU, Et3N, R1’R2’NH, MeCN, rt, 3 h, 60-90%, f) TBD, 
R1’R2’NH, MeCN, rt, 1 – 16 h 70-85%. 
The acrylic ester could not be successfully coupled under 
these conditions; we postulate that the required trialkyl-
borane may not form as the alkene is too electron deficient. 
The desired ester was synthesized by a Heck-Mizoroki 
cross-coupling and subsequent reduction of the double-
bond, before chlorination and amide formation with TBD 
(scheme 3).  
Scheme 3. Heck cross-coupled amide tail linker syn-
thesis 
 
Reaction conditions: a) ethyl acrylate, SingaCycle™, K2CO3, 
NMP, 100 °C, 16 h, 30%, b) triethylsilane, Pd/C, EtOH, rt, 16 h, 
78%, c) SO2Cl2, Et2O, rt, 96 h, 57%, d) TBD, n-butylamine, 
MeCN, 16h, 39%.  
A selection of ether chain analogues were also planned and 
synthesised (D – table 2), these were expected to be more 
chemically similar to that of the aliphatic chain with a 
smaller amount of polarity introduced in comparison to 
the amide. These compounds were less chemically tracta-
ble; in our hands the anisole de-protection to the phenol 
proved challenging. The deprotection conditions that we 
explored led to the cleavage of the desired ether function-
ality present in the chain to the terminal alcohol. To miti-
gate this synthetic hurdle, alternative protecting groups 
were investigated. Bulkier silyl protecting groups hindered 
the cross-coupling and failed to provide the desired ether 
tail analogues. Reaction with the phenolic ester (27) pro-
vided some cross-coupled product, the stability of this pro-
tecting group perhaps unsurprisingly, proved to be labile 
under the reaction coupling conditions. The de-acetylated 
products (29 to 31) were observed and isolated from the re-
actions however significant proportions of the starting ma-
terial ester (28) saponified before cross-coupling providing 
 a major by-product of the deacetylated phenol (14) thus re-
sulting in lower isolated yields (scheme 4). 
Scheme 4. Ether tail linker synthesis 
Reaction conditions: a) Ac2O, pyridine, DCM, rt, 16 h, 74%, b) 
i) BH3·THF, 1-alkene ether, 0°C, 20 min, ii) toluene, H2O, 
K3PO4, RuPhos, Pd(OAc)2, 16 h, 50 °C, 7-24%. 
Assessment of these less lipophilic analogues showed a 
large decrease in potency compared to the n-octyl ana-
logues, highlighting that even minor increases in polarity 
in this part of the lipophilic tail was not tolerated. The most 
promising analogues included polarity at the terminal of 
the chain (22 and 23); however, disappointingly, these 
compounds resulted in no measurable inhibition of T. b. 





Table 3. Biological assessment of polar tail analogues 
 
# R3 R5 cLogP TAO pIC50† T. b. b. pEC50* 
11  CH3 6.3 8.9 ± 0.3 7.6 ± 0.1 
46  H 5.8 7.0 ± 0.1 5.1 ± 0.2 
27 
 
CH3 3.5 5.5 ± 0.2 <4.3 
19 
 
H 3.0 <4.5 - 
20 
 
H 2.9 4.6 ± 0.1 - 
21 
 
H 3.0 4.6 ± 0.1 - 
22 
 
H 3.4 5.1 ± 0.1 <4.3 
23 
 
H 3.6 5.4 ± 0.2 <4.3 
29  H 4.1 4.8 ± 0.1 4.7 ± 0.1 
30  H 4.1 5.6 ± 0.1 4.6 ± 0.1 
31  H 4.1 5.2 ± 0.1 <4.3 
†: Negative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome alternative oxi-
dase; *: Negative log concentration and standard deviation of compounds required for 50% growth inhibition of T. b. brucei Lis-
ter427. (n ≥ 2 in all assays performed). 
This data suggested that a lipophilic tail was required for 
the potent inhibition of TAO. To further probe this obser-
vation; analogues were prepared to assess the length of tail 
needed for potent inhibition of TAO and whether total lip-
ophilicity could be decreased by reduction of the carbon 
chain length (E – table 2). Previous reports had shown large 
decreases in potency against TAO at carbon chain length 
below 3. The C1-7 analogues (39 to 45) were prepared in a 
similar fashion to that of the n-octyl analogue (11); C1-4 an-
alogues were however prepared directly using the alkyl bo-
ronic acid or trimeric alkyl boroxines as the volatile alkene 
hydrocarbons were not accessible (scheme 5). 
 
 
Scheme 5. Carbon chain length analogue synthesis 
  
Reaction conditions: a) i) BH3·THF, 1-alkene, 0 °C, 20 min, ii) 
toluene, H2O, K3PO4, RuPhos, Pd(OAc)2, 16 h, 50 °C, 65-90%, 
or 1-boronic acid/boroxine, K3PO4, RuPhos, Pd(OAc)2, 16 h, 80 





Table 4. Biological assessment of carbon chain length analogues 
 
# R3 cLogP TAO pIC50† T. b. b. pEC50* 
11 n-C8H17 6.3 8.9 ± 0.3 7.6 ± 0.1 
45 n-C7H15 5.8 8.5 ± 0.1 6.6 ± 0.2 
44 n-C6H13 5.4 8.2 ± 0.1 6.1 ± 0.1 
43 n-C5H11 4.9 7.8 ± 0.1 6.0 ± 0.1 
42 n-C4H9 4.5 7.7 ± 0.1 5.3 ± 0.1 
41 n-C3H7 4.1 7.1 ± 0.1 4.7 ± 0.1 
39 n-CH3 3.2 6.2 ± 0.1 4.7 ± 0.1 
†: Negative log concentration and standard deviation of compounds required for 50% inhibition of trypanosome alternative oxi-
dase; *: Negative log concentration and standard deviation of compounds required for 50% growth inhibition of T. b. brucei Lis-
ter427. (n ≥ 2 for all assays performed). 
Interestingly, the reduced carbon chain length analogues 
showed good potency against TAO (table 4), until a nota-
ble decrease in enzymatic inhibition was observed at com-
pounds with C3 or below, corroborating previous reports.22 
What was more evident was the decrease observed in effi-
cacy against T. b. brucei growth inhibition as chain length 
and cLogP decreased. Compounds showed a distinct drop 
off in potency against T. b. brucei for each carbon reduc-
tion. To interrogate this data further correlations of cLogP 




 Figure 4. Correlations of cLogP vs TAO inhibition pIC50 (left) and cLogP vs T. b. b. pIC50 growth inhibition (right). LipE is 
lipophilic ligand efficiency (pIC50 – cLogP)32. 
Biochemical potency for these compounds track to a lipo-
philic ligand efficiency of 3. Cellular potency, however cor-
relates to a lipophilic ligand efficiency of 1, relating to a 100-
fold decrease in potency from the biochemical activity to 
the cellular assay. The 2 log decrease in cellular potency 
observed here could be due a combination of reasons that 
we are currently investigating, it is of interest that CCB (2) 
shows a smaller decrease in potency from the biochemical 
to cellular assay. The permeability of the compounds 
though the cell and mitochondrial membranes of the tryp-
anosome may reduce as the lipophilicity decreases. The 
compounds could be substrates for efflux transport, that 
may reduce the intracellular concentration. The TAO inhi-
bition kinetics of the compounds may be altered with the 
reduction in carbon chain length that could result in faster 
dissociation, resulting in reduced efficacy on target. The 
compounds may not locate to the desired cell compart-
ment as lipophilicity may be required for the inhibitors to 
be retained in the inner mitochondrial membrane where 
the enzyme is located. Colletochlorin B could be acting on 
an unknown complimentary anti-parasitic target. On-go-
ing studies to better understand these data will aid future 
analogue design and synthesis to identify more drug like 
inhibitors of TAO. 
We also noticed positive correlation between cLogP and 
both biochemical and cellular activity (figure 4). Examples 
of potency correlating to high lipophilicity have previously 
been observed with other membrane proteins and en-
zymes requiring lipophilic substrates.33,34  
Conclusions 
HAT continues to provide a challenge for the development 
of new therapies; cases continue to be reported with re-
sistance more frequently observed. Discoveries of new 
brain penetrant T. b. gambiense and T. b. rhodesiense tryp-
anocides are vital for ensuring the adequate control of HAT 
in the future. Our work in this area has been to identify 
potent inhibitors of TAO that possess improved physico-
chemical properties than that of the natural products from 
which they are derived. Our exploration in this area has 
previously shown the requirement for the methyl and 
chloro substituents on the aromatic ring for high potency 
inhibition of TAO. Our efforts reported here for modulat-
ing the lipophilicity of this molecule by the introduction of 
polar functionality in the tail region of this chemotype has 
proved challenging. Polar functionality in this region of the 
molecule was shown to not be tolerated with large de-
creases in potency against TAO observed. The reduction in 
the carbon chain length of the tail resulted in identifying 
analogues that retained high inhibitory activity of TAO, 
however ex vivo efficacy against T. b. brucei growth was di-
minished. We will continue to try to understand this dis-
connect and use this generated data for future compound 
design towards more drug like inhibitors of TAO. 
Materials and Methods 
Experimental Details. ChemAxon Calculator Plugins 
were used for structure property prediction and calculation 
(cLogP), Marvin 15.5.4, 2015, ChemAxon (http://www.che-
maxon.com). All commercial reagents were purchased 
from Sigma-Aldrich, Alfa Aesar, Apollo Scientific, Fluo-
rochem or Tokyo Chemical Industry and of the highest 
available purity. Unless otherwise stated, chemicals were 
used as supplied without further purification. Anhydrous 
solvents were purchased from Acros (AcroSeal™) or Sigma-
Aldrich (SureSeal™) and were stored under nitrogen. 40-
60 petrol ether refers to the fraction with a boiling point 
between 40 °C and 60 °C. Anhydrous solvents and reagents 
were used as purchased. Thin layer chromatography (TLC) 
was carried out using glass plates pre-coated with Merck 
silica gel 60 F254. Melting points were determined using 
an OptiMelt apparatus and are uncorrected. Proton nu-
clear magnetic resonance spectra were recorded at 500 
MHz on a Varian VNMRS 500 MHz spectrometer (at 30 
°C), using residual isotopic solvent (CHCl3, δ = 7.27 ppm, 
DMSO δ = 2.50 ppm, MeOH δ = 3.31 ppm) as an internal 
reference. Chemical shifts are quoted in parts per million 
(ppm). Coupling constants (J) are recorded in Hertz (Hz). 
Carbon nuclear magnetic resonance spectra were recorded 
at 125 MHz on a Varian 500 MHz spectrometer and are pro-
ton decoupled, using residual isotopic solvent (CHCl3, δ = 
77.00 ppm, DMSO δ = 39.52 ppm, MeOH δ = 49.00 ppm) 
as an internal reference. Proton and carbon spectra assign-
ments are supported by DEPT editing. High resolution 
mass spectrometry (HRMS) data (ESI) was recorded on 
Bruker Daltonics, Apex III, ESI source: Apollo ESI with 
methanol as spray solvent. Only molecular ions, fractions 
from molecular ions and other major peaks are reported as 
mass/charge (m/z) ratios. LCMS data was recorded on a 
Waters 2695 HPLC using a Waters 2487 UV detector and a 
Thermo LCQ ESI-MS. Samples were eluted through a Phe-
nomenex Lunar 3 μm C18 50 mm × 4.6 mm column, using 
water and acetonitrile acidified by 0.1% formic acid at 1 
ml/min and detected at 254 nm. The gradient employed 
was a 7 min method 30-90% MeCN over a 5 min gradient, 
held at 90% MeCN for 1 min, then re-equilibrated to 30% 
MeCN over 1 min. All experiments were carried out under 
an inert atmosphere of N2 unless otherwise stated. 
TAO Absorbance Assay. 1-Ubiquinol turnover was meas-
ured by recording the increase in absorbance at 278 nm 
(Greiner 96-well UV star flat bottom plates with BMG 
PHERAstar FS photo spectrometer) to monitor the in-
crease of 1-ubiquinone concentration kinetically over 6 
min with purified rTAO (3 nM). A final concentration of 15 
µM 1-ubiquinol was used under the following conditions: 
50 mM Tris-HCl; 0.05% (w/v) C10E8; pH 7.4; 25 °C). The 
sigmoidal curve of the inhibition was observed by 10-point 
3-fold serial dilution of test compounds to generate IC50 
values. 
Growth inhibition assays. Bloodstream form Trypano-
soma brucei brucei Lister 427 parasites were continuously 
 passaged in HMI-9 medium formulated from IMDM me-
dium  (Invitrogen), 10% heat-inactivated fetal bovine se-
rum, 10% Serum Plus medium supplement (SAFC Biosci-
ences), 1 mM hypoxanthine (Sigma-Aldrich), 50 µM bath-
ocuproine disulfonic acid (Sigma-Aldrich), 1.5 mM cysteine 
(Sigma-Aldrich), 1 mM pyruvic acid (Sigma-Aldrich), 39 µg 
/ mL thymidine (Sigma-Aldrich), and 14 µL / L beta-mer-
capthoethanol (Sigma-Aldrich); all concentrations of 
added components refer to that in complete HMI-9 me-
dium. The parasites were cultured in 10 mL of HMI-9 me-
dium in T75 CELL-STAR tissue culture flasks at 37 °C / 5% 
CO2.  
To determine growth inhibitory potency of compounds 
against T. b. brucei bloodstream form parasites, 200 nL of 
10-point, 3-fold serially diluted compounds in DMSO were 
transferred to the wells of white, solid bottom 384-well 
plates (Greiner Bio-One) by either Echo 555 acoustic liquid 
handling system or Mosquito. Then, 104 of T. b. brucei par-
asites in 40 µL of HMI-9 medium were added to each well, 
and the plates were incubated for 48 hours at 37 °C in 5% 
CO2 incubators. Parasite numbers in individual plate wells 
were determined through quantification of intracellular 
ATP amount. The CellTiter-Glo luminescent cell viability 
reagent (Promega) was added to plate wells, and ATP-
dependent luminescence signal was measured on Tecan 
M1000 plate Reader after 30 min incubation. Suramin an 
anti-trypanosomal drug was used positive control and 
DMSO was used as negative control. pIC50 values were cal-
culated using Graph Pad Prism software by plotting the lu-
minescence values in sigmoidal dose response curves. Su-
ramin was used as a positive control in screening. (pIC50 6.7 
± 0.1) 
Hep-G2 Cytotoxicity Assay. Human hepatocellular carci-
noma (HepG2) cells were obtained from ATCC and grown 
in RPMI media. 25 µL of 1.6 x 104 cells / mL were dispensed 
into sterile 384 well Griener clear plates and incubated at 
37 °C in 5% CO2 incubator for 24 h. Once the cells adhered, 
125 nL of 10-point, 3-fold serially diluted compounds in 
DMSO were transferred on to cells. After incubating for ad-
ditional 96 h at 37 °C in 5% CO2 incubator, cells were added 
with CCK-8 reagent to each well. Plates were further incu-
bated for 3 h followed by absorbance reading at 450 nM 
using Envision reader. Absorbance values were used for de-
termination of cytotoxic concentration (pCC50) required to 
inhibit 50% growth. Purmycin was used as positive control 




To a solution of triphenylphosphine (42 mg, 0.16 mmol) in 
dichloromethane (2 mL) was added 2,3-dichloro-5,6- dicy-
ano-p-benzoquinone (37 mg, 0.16 mmol). The dark reac-
tion mixture was stirred at room temperature for 1 minute 
during which time the colour faded. 4-Chloro-2-2E)-3,7-di-
methylocta-2,6-dien-1-yl]-6-[(hydroxyimino)m ethyl]ben-
zene-1,3-diol (35 mg, 0.10 mmol) in dichloromethane (0.5 
mL) was added to the reaction mixture in 1 portion and this 
was stirred for 1 minute before being concentrated under 
reduced pressure. Purification by flash column chromatog-
raphy (10 g silica), eluting with a gradient of petrol ether : 
ethyl acetate (100 : 0) to (90 : 10), gave the title compound 
as a white solid (24 mg, 72%). 1H NMR (500 MHz, Chloro-
form-d) δ 8.60 (s, 1H), 6.10 (s, 1H), 5.42 – 5.32 (m, 1H), 5.10 
– 5.01 (m, 1H), 3.66 (d, J = 7.3 Hz, 2H), 2.58 (s, 3H), 2.11 – 
2.05 (m, 2H), 2.05 – 1.98 (m, 2H), 1.84 (d, J = 1.2 Hz, 3H), 
1.64 (d, J = 1.4 Hz, 3H), 1.57 (d, J = 1.2 Hz, 3H). 
2-Methyl-4-hydroxy-5-bromo-benzaldehyde (6) 
To a solution of 2-methyl-4-hydroxy-benzaldehyde (10 g, 
73.45 mmol) in CH2Cl2 (100 ml) and methanol (50 ml) was 
added a solution of phenyltrimethylammonium tribro-
mide (30.07 g, 77.12 mmol) in CH2Cl2 : methanol (1:1, 100 
ml) at -5 °C. The reaction was warmed to ambient temper-
ature and stirred for 16 h. The reaction was concentrated 
under reduced pressure and the residue was added 1 M HCl 
(aq) (200 mL) to precipitate a white solid, the solid was col-
lected by filtration and dried under reduced pressure to 
give the title compound as a cream precipitate (14.67 g, 94 
%): m.p. 160–165 °C, (methanol / water). IR (neat, vmax) cm-
1, 3063, 1384, 1310, 1136. 1H NMR (500MHz, D6-DMSO) δ 11.35 
(1H, br s), 9.95 (1H, s), 7.91 (1H, s), 6.83 (1H, s), 2.49 (3H, s). 
13C NMR (126MHz, D6-DMSO) δ 190.8 (CH), 159.2 (C), 142.3 
(C), 137.1 (CH), 128.0 (C), 119.1 (CH), 107.4 (C), 19.1 (CH3). 
HRMS (ESI-) m/z [M-H]- calculated for C8H6BrO2 212.9557, 
found 212.9550. 
5-Bromo-4-hydroxy-2-methyl-benzonitrile (7)  
A solution of 2-methyl-4-hydroxy-5-bromo-benzaldehyde 
(20.00 g, 93.0 mmol), in acetonitrile (300 mL) was added 
hydroxylamine hydrochloride (6.92 g, 99.5 mmol). The re-
action mixture was heated to reflux and stirred for 16 
hours. The reaction mixture was cooled to 50 °C and added 
further hydroxylamine hydrochloride (1.5 g, 21.5 mmol). 
The reaction mixture was heated to reflux for a further 3 
hours. This was collected by filtration and dried under vac-
uum to give 13.08 g of an off-white solid. Analysis showed 
a good purity product. The filtrate was concentrated under 
vacuum. The residue was triturated in MeCN : water (1:2) 
and sonicated, the solid was collected by filtration and 
dried under vacuum, to provide a further 6.67 g (19.75, 
quant.). m.p. 194-199 °C (MeCN / water). IR (neat, νmax) cm-
1 3203, 2232 (CN), 1595, 1402, 1386, 1260, 1221. 1H NMR 
(500MHz, D6-DMSO) - δ 11.38 (1H, br s), 7.90 (1H, s), 6.92 
(1H, s), 2.49 (3H, s). 13C NMR (126MHz, D6-DMSO) δ 158.6 
(C), 143.4 (C), 137.1 (CH), 117.9 (CH), 117.7 (C), 107.3 (C), 
103.8 (C), 19.1 (CH3). HRMS (ESI-) m/z [M-H]- calculated 
for C8H5BrNO 209.9560, found 209.9554. 
5-Bromo-3-chloro-4-hydroxy-2-methyl-benzonitrile (8) 
Triethylamine (0.83 mL, 5.97 mmol) was added to a solu-
tion of 5-bromo-2-methyl-4-hydroxybenzonitrile (1.15 g, 
5.42 mmol) in acetonitrile (50 mL). 1-chloropyrorolidine-
2,5-dione (1.52 g, 11.38 mmol) was added portionwise to the 
stirring solution. To the reaction mixture was added water 
(50 mL), precipitating a pale-yellow solid that was col-
lected by filtration to provide the title compound (1.11 g, 
83%). m.p. 166-169 °C, IR (neat, vmax), cm-1 3239, 2236 (CN), 
1581, 1468, 1384, 1294, 1224, 1147. 1H NMR (500MHz, CDCl3) 
δ 7.70 (s, 1H), 6.39 (s, 1H), 2.58 (s, 3H). 13C NMR (126 MHz, 
 CDCl3) δ 152.5 (C), 140.9 (C), 134.4 (CH), 122.1 (CH), 116.4 
(C), 107.5 (CH), 106.9 (C), 19.0 (CH3). HRMS (ESI-) m/z [M-
H]- calcd for C8H4BrClNO 243.9170, found 243.9165. 
5-Bromo-3-chloro-4-methoxy-2-methyl-benzonitrile (9) 
Dimethyl sulfate (0.85 mL, 8.95 mmol) was added to a sus-
pension of 5-bromo-3-chloro-4-hydroxy-benzonitrile (2.10 
g, 8.52 mmol), and potassium carbonate (1.41 g, 10.22 
mmol) in acetone (80 mL). The reaction mixture was 
heated to reflux for 3 hours, the reaction was cooled to RT 
and added water (160 mL) precipitating a white solid that 
was collected by vacuum filtration to give the title com-
pound (2.07 g, 93%). m.p. 119-120 °C, IR (neat, vmax), cm-1 
2229 (CN), 1457, 1372, 1275, 1048. 1H NMR (500 MHz, CDCl3) 
δ 7.74 (s, 1H), 3.94 (s, 3H), 2.58 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 157.4 (C), 141.7 (C), 134.9 (CH), 131.3 (C), 116.3 (C), 
116.0 (C), 111.0 (C), 61.0 (CH3), 19.2 (CH3). LRMS EI+ 261 m/z. 
3-Bromo-5-chloro-4-hydroxybenzonitrile (13) 
N-Bromosuccinimide (0.30 g, 1.71 mmol) was added to a so-
lution of 3-chloro-4-hydroxybenzonitrile (0.25g, 1.63 
mmol) in acetonitrile (5 mL). To the reaction mixture was 
added water (15 mL), precipitating a white solid, this was 
collected by filtration and dried under reduced pressure to 
provide the title compound as a white solid (0.36 g, 84%). 
m.p. 166-169 °C. IR (neat, vmax), cm-1 3411, 2229, 1471, 1327, 
1294, 1245, 1204, 1156. 1H NMR (500MHz, CDCl3) δ 7.75 (s, 
1H), 7.64 (s, 1H) 6.37 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 
152.8 (C), 135.0 (C), 132.6 (CH), 121.7 (C), 116.3 (C), 110.9 (C), 
106.1 (C). HRMS (ESI-) m/z [M-H]- calcd for C7H2BrClNO 
229.9014, found 231.8984. 
3-Bromo-5-chloro-4-methoxybenzonitrile (14) 
Dimethyl sulfate (0.15 mL, 1.61 mmol) was added to a sus-
pension of potassium carbonate (0.22 g, 1.61 mmol) and 3-
bromo-5-chloro-4-hydroxy-benzonitrile (0.30 g, 1.29 
mmol) in acetone (10 mL). The reaction mixture was 
heated to reflux for 30 min, cooled to RT and added water. 
The resulting precipitate was collected by filtration and 
dried under reduced pressure to provide the title com-
pound as a white solid (0.29 g, 90%). m.p. 115-116 °C, IR 
(neat, vmax), cm-1 2236 (CN), 1539, 1470, 1419, 1272. 1H NMR 
(500MHz, CDCl3) δ 7.78 (s, 1H), 7.66 (s, 1H), 3.97 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 157.6 (C), 135.4 (CH), 133.2 
(CH), 130.4 (C), 119.5 (C), 116.0 (C), 109.9 (C), 61.0 (CH3). 
HRMS (ESI-) m/z [M-H]- calcd for C8H5BrClNO 243.9170, 
found 243.9165. 
(2-Bromo-6-chloro-4-cyano-phenyl) acetate (28) 
3-Bromo-5-chloro-4-hydroxy-benzonitrile (500 mg, 2.15 
mmol) was dissolved in dichloromethane (10 mL), before 
pyridine (0.26 mL, 3.23 mmol) and acetic anhydride (0.24 
mL, 2.58 mmol) were added. The reaction mixture was 
stirred at room temperature for 12 h. The reaction mixture 
was taken up in water (10 mL) and the organic components 
were washed with water (2 × 10 mL). The chlorinated layer 
was separated, washed with brine (1 × 10 mL), dried over 
MgSO4, filtered and concentrated in vacuo, to give the title 
compound as a granular white solid (462 mg, 74%). m.p. 
116-119 °C; IR (neat, vmax, cm-1) 3088, 2238, 1774; 1H NMR 
(500 MHz, CDCl3) δ 7.83 (s, 1H), 7.72 (s, 1H), 2.44 (s, 3H); 
13C (126 MHz, CDCl3) δ 166.3 (C), 149.3 (C), 135.0 (CH), 132.7 
(CH), 130.3 (C), 119.3 (C), 115.7 (C), 112.2 (C), 20.3 (CH3); 
LRMS m/z (EI+) 275. 
General protocol for alkene cross-couplings 
1-Alkene (2.54 mmol) was dropwise added to an ice cooled 
solution of 1M borane in THF (0.91 mmol). This solution 
was warmed to room temperature and stirred for 15 min. 
The solution was quenched with the addition of water (0.25 
mL), and diluted with toluene (2.5 mL). Potassium phos-
phate tribasic (0.43 g, 2.03 mmol), aromatic bromide (1.01 
mmol), palladium(II) acetate (0.01 g, 0.025) mmol and 2-
dicyclohexylphosphino-2’-6’-diisopropoxybiphenyl (0.02 
g, 0.05 mmol) were added. The reaction mixture sealed and 
heated 100°C for 16 hours. The reaction mixture was parti-
tioned between water (10 mL) and EtOAc (20 mL). The or-
ganic layer was separated, dried over MgSO4, filtered and 
concentrated under vacuum. The residue was purified by 
flash silica chromatography, eluting with petroleum ether 
to 10-50% EtOAc followed by purification by preparative 
HPLC 50% MeCN in water to 100% MeCN to provide the 
title compounds (11-90%). 
3-Chloro-4-methoxy-2-methyl-5-octyl-benzonitrile (10) 
IR (neat, vmax) cm-1 2913, 2849, 2226 (CN), 1468, 1291, 1074. 
1H NMR (500 MHz, CDCl3) δ 7.36 (s, 1H), 3.87 (s, 3H), 2.62 
(t, J = 7.9 Hz, 2H), 2.57 (s, 3H), 1.61-1.55 (m, 2H), 1.36-1.27 
(m, 10H), 0.89 (t, J = 6.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 158.2 (C), 139.4 (C), 136.3 (C), 
132.0 (CH), 129.7 (C), 117.7 (C), 109.4 (C), 60.9 (CH3), 31.8 
(CH2), 30.2 (CH2), 29.7 (CH2), 29.4 (CH2), 29.3 (CH2), 29.1 
(CH2), 22.6 (CH2), 18.8 (CH3), 14.0 (CH3). 
LRMS EI+ 293 m/z. 
5-Chloro-4-methoxy-5-octylbenzonitrile (46 intermediate) 
IR (neat, vmax) cm-1 2925, 2854, 2232 (CN), 1470, 1426, 1275. 
1H NMR (500 MHz, CDCl3) δ 7.53 (s, 1H), 7.40 (s, 1H), 3.90 
(s, 3H), 2.66 (t,J= 7.9 Hz, 2H), 1.60 (m, 2H), 1.40 – 1.26 (m, 
10H), 0.90 (t, J= 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
158.2 (C), 139.7 (C), 132.4 (CH), 131.7 (CH), 128.9 (C), 117.7 
(C), 108.5 (C), 61.1 (CH3), 31.8 (CH2), 30.2 (CH2), 30.0 (CH2), 
29.4 (CH2), 29.3 (CH2), 29.1 (CH2), 22.6 (CH2), 14.0 (CH3). 




IR (neat, vmax), cm-1 2952, 2231 (CN), 1732, 1427, 1276, 993, 
877. 1H NMR (500 MHz, CDCl3) δ 7.55 (d, J = 2.1 Hz, 1H), 
7.40 (d, J = 2.1 Hz, 1H), 3.90 (s, 3H), 3.68 (s, 3H), 2.70 (t, J = 
7.7 Hz, 2H), 2.36 (t, J = 7.3 Hz, 2H), 1.92 (m, 2H). 13C NMR 
(126 MHz, CDCl3) δ 158.2 (C), 139.7 (C), 132.4 (CH), 131.7 
(CH), 128.9 (C), 117.7 (C), 108.5 (C), 61.1 (CH3), 31.8 (CH2), 
30.2 (CH2), 30.0 (CH2), 29.4 (CH2), 29.3 (CH2), 29.1 (CH2), 
22.6 (CH2), 14.0 (CH3). LRMS EI+ 267 m/z. 
Methyl 5-(3-chloro-5-cyano-2-methoxy-phenyl)pentano-
ate (16) 
IR (neat, vmax), cm-1 2951, 2233 (CN), 1733, 1472, 1275. 1H 
NMR (500 MHz, CDCl3) δ 7.53 (s, 1H), 7.38 (s, 1H), 3.89 (s, 
3H), 3.67 (s, 3H), 2.67 (m, 2H), 2.35 (m, 2H), 1.65 (m, 4H). 
13C NMR (126 MHz, CDCl3) δ 173.8 (C), 158.2 (C), 139.9 (C), 
 132.4 (C), 132.0 (C), 128.9 (C), 117.6 (C), 108.5 (C), 61.1 (CH3), 
51.6 (CH3), 33.7 (CH2), 29.7 (CH2), 29.5 (CH2), 24.6 (CH2). 
LRMS EI+ 281 m/z. 
Methyl 6-(3-chloro-5-cyano-2-methoxy-phenyl)hexanoate 
(17) 
IR (neat, vmax), cm-1 2948, 2232 (CN), 1733, 1472, 1275. 1H 
NMR (500 MHz, CDCl3) δ 7.53 (s, 1H), 7.38 (s, 1H), 3.89 (s, 
3H), 3.67 (s, 3H), 2.65 (m, 2H), 2.32 (m, 2H), 1.70-1.57 (m, 
4H), 1.39 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 174.0 (C), 
158.2 (C), 139.2 (C), 132.4 (CH), 131.9 (CH), 128.9 (C), 117.7 
(C), 108.5 (C), 61.1 (CH3), 51.5 (CH3), 33.8 (CH2), 29.82 (CH2), 
29.80 (CH2), 28.8 (CH2), 24.6 (CH2). LRMS EI+ 295 m/z. 
Methyl 7-(3-chloro-5-cyano-2-methoxy-phenyl)heptano-
ate (18) 
IR (neat, vmax), cm-1 2933, 2232 (CN), 1734, 1472, 1276. 1H 
NMR (500 MHz, CDCl3) δ 7.52 (s, 1H), 7.38 (s, 1H), 3.88 (s, 
3H), 3.66 (s, 3H), 2.64 (m, 2H), 2.31 (m, 2H), 1.66-1.55 (m, 
4H), 1.36 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 174.3 (C), 
158.4 (C), 139.6 (C), 132.6 (CH), 132.0 (CH), 129.1 (C), 117.9 
(C), 108.6 (C), 61.3 (CH3), 51.7 (CH3), 34.1 (CH2), 30.14 (CH2), 
30.08 (CH2), 29.2 (CH2), 29.0 (CH2), 24.9 (CH2). HRMS 
(ESI+) m/z [M+Na]+ calcd for C16H20ClNNaO3 332.1024, 
found 332.1019. 
3-(3-Butoxypropyl)-5-chloro-4-hydroxy-benzonitrile (29) 
IR (neat, vmax, cm-1) 2923, 2236, 1H NMR (500 MHz, CDCl3) 
7.51 (s, 1H), 7.31 (s, 1H), 3.50 (t, J = 6.6 Hz, 2H), 3.43 (t, J = 
5.9 Hz, 2H), 2.76 (t, J = 6.9 Hz, 2H), 1.90 (p, J = 6.4 Hz, 2H), 
1.62( p, J = 7.1 Hz, 2H), 1.40 (h, J = 7.5 Hz, 2H), 0.95 (t, J = 
7.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 154.9 (C), 133.0 
(CH), 131.5 (CH), 130.4 (C), 121.8 (C), 118.2 (C), 104.0 (C), 71.1 
(CH2), 68.5 (CH2), 31.5 (CH2), 29.0 (CH2), 26.4 (CH2), 19.3 
(CH2), 13.9 (CH3); HRMS (ESI-) m/z [M-H]- calcd for 
C14H17ClNO2 266.0953, found 266.0953. 
3-Chloro-5-(5-ethoxypentyl)-4-hydroxy-benzonitrile (30) 
1H (500 MHz, CDCl3) δ 7.49 (s, 1H), 7.33 (s, 1H), 3.47 (q, J = 
7.1 Hz, 2H), 3.41 (t, J = 6.3 Hz, 2H), 2.66 (t, J = 7.8 Hz, 2H), 
1.62 (p, J = 8 Hz, 4H), 1.40 (p, J = 7.8 Hz, 2H), 1.20 (t, J = 7.0 
Hz, 3H). 13C (126 MHz, CDCl3) δ 153.6 (C), 132.6 (CH), 130.4, 
(CH), 120.5 (C), 118.1 (C), 104.1 (C), 88.2 (C), 70.5 (CH2), 66.2 
(CH2), 30.2 (CH2), 29.4 (CH2), 28.7 (CH2), 26.0 (CH2), 15.1 
(CH3); HRMS (ESI-) m/z [M-H]- calcd for C14H17ClNO2 
266.0953, found 266.0942. 
3-Chloro-4-hydroxy-5-(6-methoxyhexyl)benzonitrile (31) 
IR (neat, νmax, cm-1); 2932, 2860, 2233 (CN), 1174, 1116; 1H 
NMR (500 MHz, CDCl3) δ 7.49 (s, 1H), 7.33 (s, 1H), 3.55 (s, 
3H) 3.36 (t, J = 6.6 Hz, 2H), 2.65 (t, J = 7.8 Hz, 2H), 1.57 (p, 
J = 7.4 Hz, 4H), 1.37 (m, 4H); 13C (126 MHz, CDCl3) δ 153.3 
(C), 132.7 (CH), 130.3, (CH), 120.4 (C), 110.0 (C), 100.2 (C), 
88.3 (C), 72.8 (C), 58.6 (C), 30.1 (CH2), 29.5 (CH2), 29.1 
(CH2), 28.9 (CH2), 25.9 (CH3); HRMS (ESI-) m/z [M-H]-, 
calcd for C14H17ClNO2 266.0953, found 266.0941. 
3-Chloro-4-methoxy-2-methyl-5-pentyl-benzonitrile (36) 
1H NMR - (500MHz, CDCl3) δ 7.35 (s, 1H), 3.85 (s, 3H), 2.60 
(t, J = 7.8 Hz, 2H), 2.55 (s, 3H), 1.57 (t, J = 7.5 Hz, 2H), 1.41-
1.18 (m, 4H), 0.89 (t, J = 6.7 Hz, 3H). 13C NMR - (126 MHz, 
CDCl3) δ 158.1 (C), 139.4 (C), 136.3 (C), 132.0 (CH), 129.6 (C), 
117.8 (C), 109.3 (C), 60.9 (CH3), 31.5 (CH2), 29.9 (CH2), 29.7 
(CH2), 22.4 (CH2), 18.8 (CH3), 13.9 (CH3).  
3-Chloro-5-hexyl-4-methoxy-2-methyl-benzonitrile (37) 
1H NMR - (500MHz, CDCl3) δ 7.35 (s, 1H), 3.85 (s, 3H), 2.60 
(t, J = 7.6 Hz, 2H), 2.54 (s, 3H), 1.61-1.48 (m, 2H), 1.41-1.17 
(m, 6H), 0.87 (t, J = 6.8 Hz, 3H). 13C NMR - (126 MHz, 
CDCl3) δ 158.1 (C), 139.3 (C), 136.3 (C), 132.0 (CH), 129.6 (C), 
117.7 (C), 109.3 (C), 60.9 (CH3), 31.6 (CH2), 30.1 (CH2), 29.7 
(CH2), 29.1 (CH2) 22.5 (CH2), 18.8 (CH3), 14.0 (CH3). 
3-Chloro-5-heptyl-4-methoxy-2-methyl-benzonitrile (38) 
1H NMR - (500MHz, CDCl3) δ 7.35 (s, 1H), 3.85 (s, 3H), 2.60 
(t, J = 7.9 Hz, 2H), 2.54 (s, 3H), 1.61-1.50 (m, 2H), 1.38-1.11 (m, 
8H), 0.87 (t, J = 6.7 Hz, 3H). 13C NMR - (126 MHz, CDCl3) δ 
158.1 (C), 139.3 (C), 136.3 (C), 132.0 (CH), 129.6 (C), 117.7 (C), 
109.3 (C), 60.9 (CH3), 31.7 (CH2), 30.8 (CH2), 29.7 (CH2), 
29.3 (CH2) 29.0 (CH2), 22.6 (CH2), 18.8 (CH3) 14.1 (CH3). 
General protocol for alkylboronic acid Suzuki-
Miyaura cross-coupling. 
Dicyclohexyl-[2-(2,6-diisopropoxyphenyl)phenyl]phos-
phane (9 mg, 0.02 mmol) and palladium(II) acetate (2 mg, 
0.01 mmol) was added to a degassed suspension of 5-
bromo-3-chloro-4-methoxy-2-methyl-benzonitrile (100 
mg, 0.38 mmol), boronic acid or trialkylboroxine (0.58 
mmol) and tripotassium phosphate (244 mg, 1.15 mmol) in 
toluene (2 mL). The reaction mixture was sealed, degassed, 
put under a nitrogen atmosphere and heated to 100°C for 
16-72 h. The reaction mixture was filtered through a pad of 
celite, the filtrate was partitioned between ethylacetate 
and water, the organics were separated, washed with brine, 
dried over MgSO4, filtered and concentrated under vac-
uum. The residue was purified by flash chromatography 
eluting with petroleum ether to 10%-25% ethylacetate in 
petroleum ether. Material was further purified by reverse 
phase flash chromatography, eluting with water to MeOH 
if required to provide the cross-coupled analogues de-
scribed (36-67%). 
3-Chloro-4-methoxy-2,5-dimethyl-benzonitrile (32) 
1H NMR - (500MHz, CDCl3) δ 7.35 (s, 1H), 3.84 (s, 3H), 2.55 
(s, 3H), 2.29 (s, 3H). 13C NMR - (126 MHz, CDCl3) δ 158.3 
(C), 139.5 (C), 132.9 (CH), 131.5 (C), 129.6 (C), 117.6 (C), 109.2 
(C), 60.2 (CH3), 18.8 (CH3), 16.0 (CH3). 
3-Chloro-5-ethyl-4-methoxy-2-methyl-benzonitrile (33) 
1H NMR - (500MHz, CDCl3) δ 7.37 (s, 1H), 3.86 (s, 3H), 2.75-
2.60 (m, 2H), 2.56 (s, 3H), 1.22 (t, J = 7.5 Hz, 3H). 13C NMR - 
(126 MHz, CDCl3) δ 158.0 (C), 139.4 (C), 137.5 (C), 131.4 (CH), 
129.6 (C), 117.8 (C), 109.5 (C), 60.9 (CH3), 22.3 (CH2), 18.8 
(CH3), 14.4 (CH3). 
3-Chloro-4-methoxy-2-methyl-5-propyl-benzonitrile (34) 
1H NMR - (500MHz, CDCl3) δ 7.35 (s, 1H), 3.86 (s, 3H), 2.60 
(t, J = 6.7 Hz, 2H), 2.55 (s, 3H), 1.66-1.56 (m, 2H), 0.96 (t, J 
= 7.4 Hz, 3H). 13C NMR - (126 MHz, CDCl3) δ 158.2 (C), 139.4 
(C), 136.0 (C), 132.1 (CH), 129.7 (C), 117.8 (C), 109.3 (C), 60.9 
(CH3), 31.7 (CH2), 23.3 (CH2), 18.9 (CH3), 13.9 (CH3). 
5-Butyl-3-chloro-4-methoxy-2-methyl-benzonitrile (35) 
1H NMR - (500MHz, CDCl3) δ 7.35 (s, 1H), 3.86 (s, 3H), 2.62 
(t, J = 7.7 Hz, 2H), 2.55 (s, 3H), 1.59-1.51 (m, 2H), 1.41-1.31 (m, 
 2H), 0.93 (t, 3H). 13C NMR - (126 MHz, CDCl3) δ 158.1 (C), 
139.4 (C), 136.3 (C), 132.1 (CH), 129.7 (C), 117.8 (C), 109.3 (C), 
60.9 (CH3), 32.3 (CH2), 31.7 (CH2), 22.5 (CH2), 18.8 (CH3), 
13.8 (CH3).  
General protocol for demethylation with trimethylsilyl io-
dide. 
Chloro(trimethyl)silane (0.26 mL, 2.0 mmol) was added to 
a suspension of sodium iodide (0.31 g, 2.0 mmol) and ani-
sole (0.51 mmol) in acetonitrile (2 mL). The reaction mix-
ture was heated to reflux for 4-96 hours. The cooled reac-
tion mixture was partitioned between 0.1 M sodium thio-
sulfate (10 mL) and ethyl acetate (2 x 20 mL). The organic 
layers were separated, combined dried over MgSO4, fil-
tered and concentrated under vacuum. The residue was 
purified by flash silica chromatography, eluting with petro-
leum ether to 30% ethyl acetate to provide the phenolic 
compounds (28-80%).  
3-Chloro-4-hydroxy-2-methyl-5-octyl-benzonitrile (11) 
IR (neat, vmax) cm-1 3360, 2928, 2850, 2222 (CN), 1601, 1473, 
1461, 1163. 1H NMR (500 MHz, CDCl3) δ 7.31 (s, 1H), 6.08 (s, 
1H), 2.64 (t J = 7.7 Hz, 2H), 2.56 (s, 3H), 1.59 (m, 2H), 1.45-
1.20 (m, 10H) 0.91 (t J = 7.2 Hz, 3H). 13C NMR (126MHz, 
CDCl3) δ 153.0 (C), 138.2 (C), 132.2 (CH), 128.9 (C), 121.0 (C), 
118.0 (C), 110.0 (C), 31.8 (CH2), 29.9 (CH2), 29.3 (CH2), 29.3 
(CH2), 29.2 (CH2), 29.1 (CH2), 22.6 (CH2), 18.7 (CH2), 14.0 
(CH3). HRMS (ESI-) m/z [M-H]- calculated for C16H21ClNO 
278.1317, found 278.1303.  
4-(3-Chloro-5-cyano-2-hydroxy-phenyl)butanoic acid (19 
a) 
IR (neat, vmax), cm-1 3345, 2569, 2228 (CN), 1691, 1474, 1253. 
1H NMR (500 MHz, CDCl3) δ 12.06 (br s, 1H), 10.43 (br s, 
1H), 7.81 (d, J = 2.0 Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 2.61 (t, J 
= 7.5 Hz, 2H), 2.19 (t, J = 7.5 Hz, 2H), 1.73 (quintet, J = 7.5 
Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 174.6 (C), 155.6 (C), 
133.1 (CH), 132.4 (C), 131.9 (CH), 121.6 (C), 118.7 (C), 102.8 (C), 
33.6 (CH2), 29.5 (CH2), 24.5 (CH2). HRMS (ESI-) m/z [M-H]- 
calcd for C11H9ClNO3 238.0276, found 238.0266. 
5-(3-Chloro-5-cyano-2-hydroxy-phenyl)pentanoic acid (20 
a) 
IR (neat, vmax), cm-1 3093, 2867, 2243 (CN), 1723, 1471, 1105. 
1H NMR (500 MHz, CDCl3) δ 11.98 (br s, 1H), 10.40 (br s, 
1H), 7.78 (d, J = 2.0 Hz, 1H), 7.53 (d, J = 2.0 Hz, 1H), 2.59 (t, 
J = 7.2 Hz, 2H), 2.20 (m, 2H), 1.49 (m, 4H). 13C NMR (126 
MHz, CDCl3) δ 174.8 (C), 155.6 (C), 133.8 (C), 133.0 (C), 131.8 
(C), 121.5 (C), 118.8 (C), 102.7 (C), 33.9 (CH2), 29.8 (CH2), 
28.7 (CH2), 24.5 (CH2). HRMS (ESI-) m/z [M-H]- calcd for 
C12H11ClNO3 252.0433, found 252.0423. 
6-(3-chloro-5-cyano-2-hydroxy-phenyl)-N-methyl-hexan-
amide (21 b) 
IR (neat, vmax), cm-1 3395, 2941, 2226 (CN), 1638, 1559, 1291, 
1271. 1H NMR (500 MHz, D6-DMSO) δ 10.37 (br s, 1H, OH-
7), 7.76 (s, 1H, CH-6), 7.67 (br s, 1H, NH-17), 7.51 (s, 1H, CH-
4), 2.56 (t, J = 7.14 Hz, 2H, CH2-11), 2.52 (m, 3H, CH3-19), 
2.01 (t, J = 7.2 Hz, CH2-15), 1.47 (m, 4H, CH2-12/14), 1.22 (m, 
2H, CH2-13). 13C NMR (126 MHz, D6-DMSO) δ 172.9 (C16), 
155.6 (C2), 133.2 (C3), 133.0 (CH-4), 131.7 (CH-6), 121.5 (C1), 
118.8 (C9), 102.6 (C5), 35.6 (CH2-15), 29.9 (CH2-11), 29.0 
(CH2-12), 28.8 (CH2-13), 25.8 (CH3-19), 25.5 (CH2-14). 
HRMS-ESI m/z [M+H]+ calcd for C14H17ClN2NaO2 303.0871, 
found 303.0865. 
7-(3-Chloro-5-cyano-2-hydroxy-phenyl)-N-methyl-
heptanamide (22 b) 
1H NMR - (500MHz, CDCl3) δ 7.57 (d, J = 2.0 Hz, 1H), 7.40 
(d, J = 2.0 Hz, 1H), 2.69 (s, 3H), 2.66 (t, J = 7.4 Hz, 2H), 2.16 
(t, J = 7.6 Hz, 2H), 1.70-1.50 (m, 4H), 1.44-1.22 (m, 4H). 13C 
NMR - (126 MHz, CDCl3) δ 172.4 (C), 155.2 (C),132.9 (C), 
132.1 (CH), 130.8 (CH), 121.0 (C), 117.8 (C), 102.8 (C). LRMS, 
(ESI+)[M+H]+ 295.1 m/z. 
7-(3-Chloro-5-cyano-2-hydroxy-phenyl)-N,N-dimethyl-
heptanamide (23 b) 
1H NMR - (500MHz, CDCl3) δ 7.48 (s, 1H) 7.31 (s, 1H), 6.93 
(br s, 1H), 3.00 (s, 3H), 2.96 (s, 3H), 2.69-2.59 (m, 2H), 2.34-
2.24 (m, 2H), 1.67-1.52 (m, 4H), 1.42-1.29 (m, 4H). 13C NMR 
- (126 MHz, CDCl3) δ 173.2 (C), 153.7 (C), 132.6 (CH), 132.0 
(C), 130.5 (CH), 120.8 (C), 118.2 (C), 104.1 (C), 37.3 (CH3), 35.5 
(CH3), 33.1 (CH2), 29.9 (CH2), 28.83 (CH2), 28.80 (CH2), 
28.75 (CH2), 24.6 (CH2). LRMS, (ESI+) [M+H]+ 309.1 m/z. 
3-Chloro-4-hydroxy-2,5-dimethyl-benzonitrile (39) 
1H NMR - (500MHz, CDCl3) δ 7.29 (s, 1H), 6.21 (br s, 1H), 
2.53 (s, 3H), 2.25 (s, 3H). 13C NMR - (126 MHz, CDCl3) δ 153.4 
(C), 138.3 (C), 132.8 (CH), 124.2 (C), 120.8 (C), 118.0 (C), 104.9 
(C), 18.7 (CH3), 15.9 (CH3). LRMS, (ESI-) [M-H]- 179.9 m/z. 
3-Chloro-5-ethyl-4-hydroxy-2-methyl-benzonitrile (40) 
1H NMR - (500MHz, CDCl3) δ 7.32 (s, 1H), 6.14 (s, 1H), 2.66 
(q, J = 7.6 Hz, 2H), 2.54 (s, 3H), 1.21 (t, J = 7.6 Hz, 3H). 13C 
NMR - (126 MHz, CDCl3) δ 153.0 (C), 138.3 (C), 131.4 (CH), 
130.1 (C), 121.0 (C), 118.1 (C), 105.2 (C), 23.1 (CH2), 18.8 (CH3), 
13.4 (CH3). LRMS, (ESI-) [M-H]- 194.0 m/z. 
3-Chloro-4-hydroxy-2-methyl-5-propyl-benzonitrile (41) 
1H NMR - (500MHz, CDCl3) δ 7.29 (s, 1H), 6.21 (br s, 1H), 
2.60 (t, J = 7.7 Hz, 2H), 2.53 (s, 3H), 1.62-1.56 (m, 2H), 0.94 
(t, J = 7.3 Hz, 3H). 13C NMR - (126 MHz, CDCl3) δ 153.2 (C), 
138.3 (C), 132.2 (CH), 128.7 (C), 121.1 (C), 118.1 (C), 105.0 (C),  
31.9 (CH2), 22.2 (CH2), 18.8 (CH3), 13.7 (CH3). LRMS (ESI-) 
[M-H]- 207.9 m/z 
5-Butyl-3-chloro-4-hydroxy-2-methyl-benzonitrile (42) 
1H NMR - (500MHz, CDCl3) δ 7.29 (s, 1H), 6.22 (br s, 1H), 
2.61 (t, J = 7.8 Hz, 2H), 2.53 (s, 3H), 1.60-1.50 (m, 2H), 1.40-
1.29 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H). 13C NMR - (126 MHz, 
CDCl3) δ 153.2 (C), 138.2 (C), 132.1 (CH), 128.9 (C), 121.1 (C), 
118.1 (C), 105.0 (C), 31.2 (CH2), 29.6 (CH2), 22.3 (CH2), 18.7 
(CH3), 13.8 (CH3). LRMS (ESI-), [M-H]- 221.9 m/z. 
3-Chloro-4-hydroxy-2-methyl-5-pentyl-benzonitrile (43) 
1H NMR - (500MHz, CDCl3) δ 7.30 (s, 1H), 6.10 (br s, 1H), 
2.62 (t, J = 7.8 Hz, 2H), 2.54 (s, 3H), 1.65-1.52 (m, 2H), 1.37-
1.27 (m, 4H), 0.89 (t, J = 6.8 Hz, 3H). 13C NMR - (126 MHz, 
CDCl3) δ 153.1 (C), 138.2 (C), 132.2 (CH), 128.9 (C), 121.0 (C), 
118.1 (C), 105.1 (C), 31.4 (CH2), 29.9 (CH2), 28.8 (CH2), 22.4 
(CH2), 18.8 (CH3), 14.0 (CH3). LRMS, (ESI-) [M-H]- 235.9 
m/z. 
3-Chloro-5-hexyl-4-hydroxy-2-methyl-benzonitrile (44) 
 1H NMR - (500MHz, CDCl3) δ 7.29 (s, 1H), 6.18 (br s, 1H), 
2.61 (t, J = 7.8 Hz, 2H), 2.53 (s, 3H), 1.61-1.50 (m, 2H), 1.38-
1.23 (m, 6H), 0.92-0.84 (m, 3H). 13C NMR - (126 MHz, 
CDCl3) δ 153.1 (C), 138.2 (C), 132.2 (CH), 128.9 (C), 121.0 (C), 
118.1 (C), 105.0 (C), 31.6 (CH2), 30.0 (CH2), 29.0 (CH2), 28.9 
(CH2), 22.6 (CH2), 18.8 (CH3), 14.1 (CH3). LRMS, (ESI-) [M-
H]- 249.9 m/z. 
3-Chloro-5-heptyl-4-hydroxy-2-methyl-benzonitrile (45) 
1H NMR - (500MHz, CDCl3) δ 7.30 (s, 1H), 6.11 (br s, 1H), 
2.61 (t, J = 7.5, 2H), 2.54 (s, 3H), 1.61-1.53 (m, 2H), 1.35-1.22 
(m, 8H), 0.88 (t, J = 6.2 Hz, 3H). 13C NMR - (126 MHz, 
CDCl3) δ 153.1 (C), 138.2 (C), 132.2 (CH), 128.9 (C), 121.0 (C), 
118.1 (C), 105.1 (C), 31.7 (CH2), 30.0 (CH2), 29.2 (CH2) 29.09 
(CH2), 29.06 (CH2), 22.6 (CH2), 18.8 (CH3), 14.1 (CH3). 
LRMS, (ESI-), [M-H]- 264.0 m/z. 
5-Chloro-4-hydrox-5-octylbenzonitrile (46) 
m.p. 60.1 – 61.8 °C. IR (neat, vmax) cm-1 3362, 2927, 2849, 
2230 (CN), 1595, 1471, 1316, 1241, 1168. 1H NMR (500 MHz, 
CDCl3) δ 7.49 (s, 1H), 7.34 (s, 1H), 6.07 (s, 1H), 2.66 (m, 2H), 
1.59 (m, 2H), 1.49-1.17 (m, 10H), 0.88 (m, 3H). 13C NMR (126 
MHz, CDCl3) δ 153.4 (C), 132.9 (C), 132.2 (CH), 130.4 (CH), 
120.5 (C), 118.2 (CH), 104.6 (C), 32.0 (CH2), 30.3 (CH2), 29.5 
(CH2), 29.5 (CH2), 29.4 (CH2), 29.2 (CH2), 22.8 (CH2), 14.3 
(CH3). HRMS (ESI-) m/z [M-H]- calcd for C15H19ClNO 
264.1161, found 264.1151. 
General protocol for HATU amide coupling. 
Triethylamine (0.07 mL, 0.49 mmol) was added to a solu-
tion of carboxylic acid (0.2 mmol), HATU (0.08 g, 0.22 
mmol), and amine (0.3 mmol) in acetonitrile (0.5 mL). The 
reaction was stirred at RT for 16 h. The reaction mixture 
was partitioned between ethyl acetate (5 mL) and water (5 
mL). The organic layer was separated, washed with brine, 
dried over MgSO4, filtered and concentrated under re-
duced pressure. The residue was purified by flash silica 
chromatography eluting with petroleum ether to ethyl ac-
etate in petroleum ether, then further purified by reverse 
phase chromatography eluting with water to MeOH if nec-
essary to provide the amides described (29-67%). 
4-(3-Chloro-5-cyano-2-hydroxy-phenyl)-N-propyl-bu-
tanamide (19 b) 
1H NMR - (500MHz, CDCl3) δ 10.73 (br s, 1H), 7.95 (br t, 1H), 
7.73 (s, 1H), 7.45 (s, 1H), 2.97, (m, 2H), 2.56 (t, J = 7.4 Hz, 
2H), 2.04 (t, J = 7.4 Hz, 2H), 1.71 (m, 2H), 1.37 (m, 2H), 0.81 
(t, J = 7.4 Hz, 3H). 13C NMR - (126 MHz, CDCl3) δ 172.0 (C), 
155.4 (C), 132.8 (CH), 131.9 (C), 131.4 (CH), 121.2 (C), 118.3 (C), 
102.12 (C), 40.3 (CH2), 34.3 (CH2), 29.1 (CH2), 25.0 (CH2), 
22.3 (CH2), 11.4 (CH3). LRMS, (ESI-) [M-H]- 281.0 m/z. 
5-(3-Chloro-5-cyano-2-hydroxy-phenyl)-N-ethyl-pentana-
mide (20 b) 
IR (neat, vmax), cm-1 3353, 2945, 2231 (CN), 1649, 1560, 1462, 
1174. 1H NMR - (500MHz, D6-DMSO) δ 10.16 (br 1H), 7.76-
7.72 (br m, 2H), 7.49 (s, 1H), 3.02 (m, 2H), 2.58 (t, J = 6.3 
Hz, 2H), 2.02 (t, J = 6.3 Hz, 2H), 1.45 (m, 4H), 0.96 (t, J = 7.2 
Hz, 3H). 13C NMR - (126 MHz, D6-DMSO) δ 172.1 (C), 156.0 
(C), 133.0 (C), 132.9 (C), 131.7 (C), 121.6 (C), 118.9 (C), 102.1 
(C), 35.7 (CH2), 33.6 (CH2), 29.9 (CH2), 28.9 (CH2), 25.4 
(CH2), 15.2 (CH3). HRMS (ESI+) m/z [M+Na]+ calcd for 
C14H17ClN2NaO2 303.0871, found 303.0865. 
Ethyl(2E)-3-5-cyano-2-hydroxy-4-methylphenyl)prop-2-
enoate (24) 
Potassium carbonate (0.98 g, 7.07 mmol) was added to a 
solution of 5-bromo-4-hydroxy-2-methyl-benzonitrile 
(0.50 g, 2.36 mmol) and ethyl acrylate (0.77 mL, 7.07 mL) 
in 1-methyl-2-pyrrolidinone (10 mL). [1,3-bis(2,4,6-trime-
thylphenyl)-2,3-dihydro-1H-imidazol-2-ylidene]({2-[(di-
methylamino)methyl]phenyl})palladiumylium chloride 
(SingaCycle®) was added to the suspension and the reac-
tion was sealed under nitrogen and heated at 100°C for 48 
h. The reaction mixture was cooled to RT and diluted with 
ethyl acetate (50 mL) and filtered through a celite pad. The 
filtrate was washed with 1M HCl (aq) (25 mL), 0.5 M LiCl 
(aq) (25 mL), brine (25 mL), dried over MgSO4 filtered and 
concentrated under vacuum. The residue was purified by 
flash silica chromatography eluting with petroleum ether 
to 15% ethyl acetate in petroleum ether to provide the title 
compound as a white solid (0.16 g, 29%). m.p. 142.6-149.8 
°C. IR (neat, vmax), cm-1 2923, 2221, 1600, 1274. 1H NMR (500 
MHz, D6-DMSO) δ 11.30 (br s, 1H) 8.07 (s, 1H), 7.73 (d, J = 
16 Hz, 1H), 6.90 (s, 1H), 6.70 (d, J = 16 Hz, 1H), 4.17 (d, J = 
7.2 Hz, 2H), 2.38 (s, 3H), 1.24 (t, J = 7.2 Hz, 3H). 13C NMR 
(126 MHz, D6-DMSO) δ 160.9 (C), 160.6 (C), 145.4 (C), 138.2 
(CH), 134.4 (CH), 120.3 (C), 119.4 (CH), 118.5 (C), 118.1 (CH), 
103.19 (CN), 60.4 (CH2), 20.5 (CH3), 14.6 (CH3) HRMS (ESI-
) m/z [M-H]- calcd for C13H12NO3 230.0823, found 230.0814. 
Ethyl 3-(5-cyano-2-hydroxy-4-methyl-phenyl)propanoate 
(25) 
Triethylsilane (0.50 g, 4.32 mmol) was added to a solution 
ethyl (E)-3-(5-cyano-2-hydroxy-4-methyl-phenyl)prop-2-
enoate (0.10 g, 0.43 mmol) and 10% palladium on carbon (4 
mg, 0.04 mmol) in ethanol (5 mL). The reaction mixture 
was stirred at RT for 16 h. Further triethylsilane (0.50 g, 4.32 
mmol) was added and the reaction mixture was stirred for 
a further 16 h.  The nitrogen purged reaction mixture was 
filtered through a pad of celite, the filtrate was partitioned 
between 1M HCl (aq) (10 mL) and ethyl acetate (2 x 20 mL). 
The combined organics were separated, dried over MgSO4, 
filtered and concentrated under vacuum. The residue was 
purified by flash silica chromatography, eluting with petro-
leum ether to 50% ethyl acetate in petroleum ether to pro-
vide the title compound as a white solid (0.08 g, 77%). IR 
(neat, vmax), cm-1 3496, 2927, 2225 (CN), 1716, 1199, 1250. 1H 
NMR (500 MHz, CDCl3) δ 8.25 (s, 1H), 7.32 (s, 1H), 6.80 (s, 
1H), 4.16 (q, J = 7.3 Hz, 2H), 2.84 (m, 2H), 2.70 (m, 2H), 2.44 
(s, 3H), 1.25 (t, J = 7.3 Hz). 13C NMR (126 MHz, CDCl3) δ 
175.9 (C), 158.4 (C), 142.5 (C), 135.1 (CH), 125.8 (C), 119.0 
(CH), 118.6 (C), 104.3 (C), 61.8 (CH2), 35.0 (CH2), 24.0 (CH2), 
20.1 (CH3), 14.0 (CH3). HRMS (ESI+) m/z [M+H]+ calcd for 
C13H15NNaO3 256.0944, found 256.0941.  
Ethyl 3-(3-chloro-5-cyano-2-hydroxy-4-methyl-phe-
nyl)propanoate (26) 
Sulfuryl chloride (0.02 mL, 0.26 mmol) was added to a so-
lution ethyl 3-(5-cyano-2-hydroxy-4-methyl-phenyl)pro-
panoate (0.05 g, 0.21 mmol) in diethyl ether (1 mL). The re-
action mixture was stirred at RT for 96 h. Further sulfuryl 
 chloride (0.02 mL, 0.26 mmol) was added and the reaction 
mixture was stirred for a further 16 hours.  The reaction 
mixture was partitioned between 1M HCl (aq) (10 mL) and 
ethyl acetate (2 x 20 mL). The combined organics were sep-
arated, dried over MgSO4, filtered and concentrated under 
vacuum. The residue was purified by flash silica chroma-
tography, eluting with petroleum ether to 25% ethyl ace-
tate in petroleum ether to provide the title compound as a 
white solid (0.043 g, 75%). IR (neat, vmax), cm-1 3340, 2997, 
2228 (CN), 1712, 1210, 1177. 1H NMR (500 MHz, CDCl3) δ 7.33 
(s, 1H), 7.03 (s, 1H), 4.14 (q, J = 7.1 Hz, 2H), 2.94 (t, J = 7.1 
Hz, 2H), 2.65 (t, J = 7.1 Hz, 2H), 2.55 (s, 3H), 1.24 (t, J = 7.1 
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.6 (C), 153.6 (C), 
139.4 (C), 132.6 (CH), 126.7 (C), 117.9 (C), 105.3 (C), 61.1 
(CH2), 33.7 (CH2), 25.3 (CH2), 18.9 (CH3), 14.2 (CH3). HRMS 
(ESI-) m/z [M-H]- calcd for C13H13NO3 266.0589, found 
266.0576. 
General protocol for 1,5,7-triazabicyclo[4.4.0]dec-5-
ene amide formation.  
Amine (0.33 mmol) was added to a solution of 1,5,7-
triazabicyclo[4.4.0]dec-5-ene (0.04 g, 0.26 mmol) and ester 
(0.13 mmol) in acetonitrile (0.5 mL). The reaction was 
stirred at RT for 5-40 h. The reaction mixture was parti-
tioned between ethyl acetate (25 mL) and water (25 mL). 
The organic layer was separated, washed with brine, dried 
over MgSO4, filtered and concentrated under reduced 
pressure. The residue was purified by flash silica chroma-
tography eluting with petroleum ether to 30-50% ethyl ac-
etate in petroleum ether to provide the amides described 
(27-80%).  
6-(3-Chloro-5-cyano-2-methoxy-phenyl)-N-methyl-hex-
anamide (21 a) 
IR (neat, vmax), cm-1 3300, 2938, 2230 (CN), 1639, 1557, 1281. 
1H NMR - (500MHz, CDCl3) δ 7.52 (d, J = 2.0 Hz, 1H), 7.37 
(d, J = 2.0 Hz, 1H), 5.44 (br s, 1H), 3.88 (s, 3H), 2.80 (d, J = 
5.0 Hz, 3H), 2.65 (t, J = 7.6 Hz, 2H), 2.17 (t, J = 7.6 Hz, 2H), 
1.68 (m, 2H), 1.59 (m, 2H), 1.37 (m, 2H). 13C NMR - (126 
MHz, CDCl3) δ 173.5 (C), 158.4 (C), 139.4 (C), 132.6 (CH), 
132.0 (CH), 129.1 (C), 117.8 (C), 108.6 (C), 61.3 (CH3), 36.6 
(CH2), 30.1 (CH2), 30.0 (CH2), 29.1 (CH2), 26.4 (CH2), 25.5 
(CH3). HRMS (ESI+) m/z [M+Na]+ calcd for 
C15H19ClN2NaO2 317.1027, found 317.1019. 
7-(3-Chloro-5-cyano-2-methoxy-phenyl)-N-methyl-
heptanamide (22 a)  
1H NMR - (500MHz, CDCl3) δ 7.52 (d, J = 2.0 Hz, 1H), 7.37 
(d, J = 2.0 Hz, 1H), 5.41 (br s, 1H), 3.88 (s, 3H), 2.80 (d, J = 
5.0 Hz, 3H), 2.64 (t, J = 7.9 Hz, 2H), 2.16 (t, J = 7.6 Hz, 2H), 
1.69-1.52 (m, 4H), 1.42-1.28 (m, 4H). 13C NMR - (126 MHz, 
CDCl3) δ 173.5 (C), 158.2 (C), 139.4 (C), 132.4 (C), 131.8 (C), 
128.9 (C), 117.7 (C), 108.4 (C), 61.1 (CH3), 36.6 (CH2), 30.0 
(CH2), 29.9 (CH2), 29.1 (CH2), 29.0 (CH2), 26.3 (CH3), 25.5 
(CH2). LRMS, (ESI+) [M+H]+ 309.1 m/z. 
7-(3-Chloro-5-cyano-2-methoxy-phenyl)-N,N-dimethyl-
heptanamide (23 a) 
1H NMR - (500MHz, CDCl3) δ 7.52 (s, 1), 7.37 (s, 1H), 3.88 (s, 
3H), 2.99 (s, 3H), 2.94 (s, 3H), 2.64 (m, 2H), 2.30 (m, 2H), 
1.70-1.53 (m, 4H), 1.43-1.32 (m, 4H). 13C NMR - (126 MHz, 
CDCl3) δ 173.0 (C), 158.2 (C), 139.5 (C), 132.4 (C), 131.8 (C), 
128.9 (C), 117.7 (C), 108.4 (C), 61.1 (CH3, 37.3 (CH3), 35.4 
(CH3), 33.2 (CH2), 30.1 (CH2), 29.9 (CH2), 29.2 (CH2), 29.2 
(CH2), 25.0 (CH2). LRMS, (ESI+) [M+H]+ 323.1 m/z. 
N-Butyl-3-(3-chloro-5-cyano-2-hydroxy-4-methyl-phe-
nyl)propenamide (27) 
IR (neat, vmax), cm-1 3369, 2928, 2220 (CN), 1632, 1562, 1157. 
1H NMR (500MHz, CDCl3) δ 10.35 (br s, 1H), 7.24 (s, 1H), 
5.55 (br s, 1H), 3.26 (m, 2H), 2.91 (m, 2H), 2.59 (m, 2H), 2.54 
(s, 3H), 1.45 (m, 2H), 1.28 (m, 2H), 0.90 (t, J = 7.5 Hz, 3H). 
13C NMR - (126 MHz, CDCl3) δ 173.6 (C), 155.6 (C), 140.0 (C), 
132.6 (CH), 127.4 (C), 123.9 (C), 118.3 (C), 104.0 (C), 39.9 
(CH2), 36.3 (CH2), 31.4 (CH2), 25.0 (CH2), 19.9 (CH2), 18.9 
(CH3), 13.6 (CH3). HRMS (ESI+) m/z [M+Na]+ calcd for 
C15H19ClN2NaO2 317.1027, found 317.1019. 
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